GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Thermo Fisher Scientific Inc (NYSE:TMO) » Definitions » Debt-to-EBITDA

Thermo Fisher Scientific (Thermo Fisher Scientific) Debt-to-EBITDA

: 2.94 (As of Dec. 2023)
View and export this data going back to 1980. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Thermo Fisher Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3,609 Mil. Thermo Fisher Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $31,308 Mil. Thermo Fisher Scientific's annualized EBITDA for the quarter that ended in Dec. 2023 was $11,876 Mil. Thermo Fisher Scientific's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.94.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Thermo Fisher Scientific's Debt-to-EBITDA or its related term are showing as below:

TMO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.15   Med: 3.08   Max: 4.16
Current: 3.15

During the past 13 years, the highest Debt-to-EBITDA Ratio of Thermo Fisher Scientific was 4.16. The lowest was 2.15. And the median was 3.08.

TMO's Debt-to-EBITDA is ranked worse than
68.87% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.8 vs TMO: 3.15

Thermo Fisher Scientific Debt-to-EBITDA Historical Data

The historical data trend for Thermo Fisher Scientific's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thermo Fisher Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.53 2.15 2.91 2.89 3.15

Thermo Fisher Scientific Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.98 3.50 3.26 2.96 2.94

Competitive Comparison

For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thermo Fisher Scientific Debt-to-EBITDA Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Thermo Fisher Scientific's Debt-to-EBITDA falls into.



Thermo Fisher Scientific Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Thermo Fisher Scientific's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3609 + 31308) / 11079
=3.15

Thermo Fisher Scientific's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3609 + 31308) / 11876
=2.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Thermo Fisher Scientific  (NYSE:TMO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Thermo Fisher Scientific Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Thermo Fisher Scientific's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Thermo Fisher Scientific (Thermo Fisher Scientific) Business Description

Address
168 Third Avenue, Waltham, MA, USA, 02451
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%).
Executives
Marc N Casper officer: Senior Vice President C/O THERMO FISHER SCIENTIFIC, 168 THIRD AVENUE, WALTHAM MA 02451
Gianluca Pettiti officer: Executive Vice President C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Stephen Williamson officer: Sr. VP and CFO 81 WYMAN STREET, WALTHAM MA 02451
Jennifer M Johnson director C/O FRANKLIN RESOURCES, INC., ONE FRANKLIN PARKWAY, SAN MATEO CA 94403-1906
Michael A Boxer officer: Sr. VP and Gen. Counsel 168 THIRD AVENUE, WALTHAM MA 02451
Lisa P. Britt officer: Sr. VP and Chief HR Officer 168 THIRD AVENUE, WALTHAM MA 02451
Jim P Manzi director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Debora L Spar director C/O GOLDMAN, SACHS & CO., 200 WEST STREET, NEW YORK NY 10282
Michel Lagarde officer: Senior Vice President 450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017
Ruby R Chandy director 630 DUNDEE ROAD, SUITE 400, NORTHBROOK IL 60062
Mark P Stevenson officer: Executive Vice President 850 LINCOLN CENTRE DRIVE, FOSTER CITY CA 94404
Joseph R. Holmes officer: VP & Chief Accounting Officer 168 THIRD AVENUE, WALTHAM MA 02451
R. Alexandra Keith director ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Peter E Hornstra officer: Chief Accounting Officer 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Syed A. Jafry officer: Sr. Vice President 345 E. MAIN STREET, WARSAW IN 46580